Multiple myeloma (MM), constituting 10% of hematological malignancies, poses significant morbidity and mortality, especially with skeletal involvement. Bisphosphonate use in MM may lead to severe hypocalcemia due to vitamin D deficiency (VDD), exacerbating bone-marrow plasma cell burden. We aimed to assess VDD prevalence and its impact on outcomes in MM patients. A retrospective cross-sectional analysis (2008–2018) of nationwide inpatient data identified adult MM hospitalizations with VDD using ICD-10-CM codes. Univariate and multivariate analyses were conducted to evaluate prevalence, demographics, and outcomes, with significance set at p < 0.05. Among 330,175 MM hospitalizations, 3.48% had VDD. VDD was more prevalent among 50–75 year olds (61.72% vs 59.74%), females (53.36% vs 44.34%), Blacks (23.34% vs 22.94%), Whites (65.84% vs 65.79%), higher income brackets (26.13% vs 23.85%), and those with comorbidities like hypertension (71.12% vs 69.89%), dyslipidemia (42.47% vs 34.98%), obesity (13.63% vs 10.19%), and alcohol abuse (1.61% vs 1.34%). In regression analysis, VDD in MM patients correlated with higher morbidity (adjusted odds ratio (aOR): 1.24, 95% confidence interval (95% CI): 1.14–1.36) and major disability (aOR: 1.26, 95% CI: 1.20–1.30). MM patients with VDD exhibit worse outcomes, underscoring the importance of recognizing and managing VDD promptly. Further prospective studies are needed to validate our findings and explore the impact of vitamin D supplementation on MM patient outcomes.
U.S. Cancer Statistics Working Group.U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999–2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2023. https://www.cdc.gov/cancer/dataviz3
2.
NathKGaneshalingamVEwartB, et al. A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia. Support Care Cancer2020; 28(3): 1249–1254.
YellapragadaSVFillmoreNRFrolovA, et al. Vitamin D deficiency predicts for poor overall survival in white but not African American patients with multiple myeloma. Blood Adv2020; 4(8): 1643–1646.
5.
KazandjianDLandgrenO. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol2016; 43(6): 682–689.
6.
EicherFMansouri TaleghaniBSchildC, et al. Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels. Hematol Oncol2020; 38(4): 523–530.
7.
RothDEAbramsSAAloiaJ, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci2018; 1430(1): 44–79.
8.
MaierGSHorasKKurthAA, et al. Prevalence of vitamin D deficiency in patients with bone metastases and multiple myeloma. Anticancer Res2015; 35(11): 6281–6285.
9.
ClementZAshfordMSivakumaranS. Vitamin D deficiency in a man with multiple myeloma. N Am J Med Sci2011; 3(10): 469–471.
10.
InnaoVAllegraAGinaldiL, et al. Reviewing the significance of vitamin D substitution in monoclonal gammopathies. Int J Mol Sci2021; 22(9): 4922.
11.
IsodaAMiyazawaYIshikawaT, et al. Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study. Support Care Cancer2023; 31(9): 547.
12.
RoodmanGDMultiple Myeloma Research Foundation. Myeloma bone disease: pathogenesis and treatment. Oncology (Williston Park)2005; 19(8): 983–984, 986.
13.
Noriega AldaveAPJaiswalS. Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report. J Med Case Rep2014; 8(1): 353.
14.
BadrosAGoloubevaOTerposE, et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol2008; 142(3): 492–494.
15.
NgACKumarSKRajkumarSV, et al. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol2009; 84(7): 397–400.
16.
GallagherJC. Vitamin D and aging. Endocrinol Metab Clin North Am2013; 42(2): 319–332.
17.
BenjaminMReddySBrawleyOW. Myeloma and race: a review of the literature. Cancer Metastasis Rev2003; 22(1): 87–93.
18.
ForrestKYZStuhldreherWL. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res2011; 31(1): 48–54.
19.
GindeAALiuMCCamargoCA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med2009; 169(6): 626.
20.
HolickMFBinkleyNCBischoff-FerrariHA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2011; 96(7): 1911–1930.
21.
BoydKDRossFMChiecchioL, et al. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev2011; 20(8): 1703–1707.
22.
AmreinKScherklMHoffmannM, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr2020; 74(11): 1498–1513.
23.
WimalawansaSJ. Vitamin D and cardiovascular diseases: causality. J Steroid Biochem Mol Biol2018; 175: 29–43.
24.
VaidyaAFormanJP. Vitamin D and hypertension. Hypertension2010; 56(5): 774–779.
25.
BaiLQuCFengY, et al. Evidence of a casual relationship between vitamin D deficiency and hypertension: a family-based study. Hypertens Res2022; 45(11): 1814–1822.
26.
AlagaconeSVergaEVerdoliniR, et al. The association between vitamin D deficiency and the risk of resistant hypertension. Clin Exp Hypertens2020; 42(2): 177–180.
27.
KimMRJeongSJ. Relationship between vitamin D level and lipid profile in non-obese children. Metabolites2019; 9(7): 125.
28.
AlQuaizAMKaziAYoussefRM, et al. Association between standardized vitamin 25(OH)D and dyslipidemia: a community-based study in Riyadh, Saudi Arabia. Environ Health Prev Med2020; 25(1): 4.
29.
LongJZhangC-JZhuN, et al. Lipid metabolism and carcinogenesis, cancer development. Am J Cancer Res2018; 8(5): 778–791.
30.
PedersenKMÇolakYBojesenSE, et al. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals. J Hematol Oncol2020; 13(1): 129.
31.
ChoiTChoiIYHanK, et al. Lipid level, lipid variability, and risk of multiple myeloma: a nationwide population-based study of 3,527,776 subjects. Cancers (Basel)2021; 13(3): 540.
32.
SurduAMPînzariuOCiobanuD-M, et al. Vitamin D and its role in the lipid metabolism and the development of atherosclerosis. Biomedicines2021; 9(2): 172.
33.
ManousopoulouAAl-DaghriNMGarbisSD, et al. Vitamin D and cardiovascular risk among adults with obesity: a systematic review and meta-analysis. Eur J Clin Invest2015; 45(10): 1113–1126.
34.
NormanPEPowellJT. Vitamin D and cardiovascular disease. Circ Res2014; 114(2): 379–393.
35.
RaslanESolimanSSANourZA, et al. Association of vitamin D deficiency with chronic stable angina: a case control study. High Blood Press Cardiovasc Prev2019; 26(1): 77–80.
36.
LiuXBaylinALevyPD. Vitamin D deficiency and insufficiency among US adults: prevalence, predictors and clinical implications. Br J Nutr2018; 119(8): 928–936.
37.
LauterBSchmidt-WolfIGH. Prevalence, supplementation, and impact of vitamin D deficiency in multiple myeloma patients. Cancer Invest2015; 33(10): 505–509.
38.
KyleRAYeeGCSomerfieldMR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007; 25(17): 2464–2472.
39.
TerposEMorganGDimopoulosMA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease. J Clin Oncol2013; 31(18): 2347–2357.
40.
KimSChoHKimM, et al. The prognostic significance of vitamin D deficiency in Korean patients with multiple myeloma. Clin Lymphoma Myeloma Leuk2024; 24(3): e112–e118.
41.
MirhosseiniNPsihogiosAMcLarenMD, et al. Vitamin D and multiple myeloma: a scoping review. Curr Oncol2023; 30(3): 3263–3276.
